AVITA Medical, Inc.

Amendment and Restatement of Bylaws

On November 4, 2026, the Board of Directors (the “Board”) of AVITA Medical, Inc. (the “Company”) approved and adopted the Company's Amended and Restated Bylaws (the “Amended Bylaws”), effective immediately. Among other things, the Amended Bylaws:

•

permit stockholder meetings to be held solely by remote communication;

•

revise the procedures for stockholder meetings and nominations, including (i) a requirement that stockholders requesting a special meeting have held their shares of record continuously for at least one year and (ii) enhanced advance notice requirements for stockholder nominations and proposals; including additional disclosure, a nominee questionnaire and representation, and requirements to update any such nomination and proposal up to the shareholder meeting date;

•

address the SEC's universal proxy rules (Rule 14a-19), including (i) a requirement that any stockholder nominating directors must solicit holders of at least 67% of the voting power, and (ii) reserving the white proxy card for the Board's exclusive use;

•

require that stockholder notices to the Company be delivered in writing by hand or certified mail; and

•

make other updates, including certain technical, conforming, and clarifying changes.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended Bylaws, which is filed as Exhibit 3.3 to this Quarterly Report on Form 10-Q and incorporated herein by reference.

Borrowing under Credit Agreement

On November 3, 2026, the Company borrowed an additional $10.0 million under the Credit Agreement with the Lender. The terms of payment and material terms of the Credit Agreement are described in the Form 8-K filed by the Company on January 13, 2026.